Targeting heme-oxidized soluble guanylate cyclase: Solution for all cardiorenal problems in heart failure?

Hypertension

Volumn 49, Issue 5, 2007, Pages 974-976

  Münzel, Thomas ^a   Genth Zotz, Sabine ^a   Hink, Ulrich ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; GUANYLATE CYCLASE; HEME; HYDRALAZINE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; BENZOIC ACID DERIVATIVE;

ARTERIAL PRESSURE; CENTRAL VENOUS PRESSURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG MECHANISM; DRUG TARGETING; EDITORIAL; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART OUTPUT; HUMAN; KIDNEY BLOOD FLOW; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VASCULAR SMOOTH MUSCLE; ANIMAL; CHEMISTRY; DOSE RESPONSE; ENZYME ACTIVATION; HEART; KIDNEY; METABOLISM; NOTE; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; SOLUBILITY;

ANIMALS; BENZOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GUANYLATE CYCLASE; HEART; HEART FAILURE, CONGESTIVE; HEME; HUMANS; KIDNEY; OXIDATION-REDUCTION; SOLUBILITY;

EID: 34247847737     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.106.085456     Document Type: Editorial

References (11)

1. Mollnau H, Oelze M, August M, Wendt M, Daiber A, Schulz E, Baldus S, Kleschyov AL, Materne A, Wenzel P, Hink U, Nickenig G, Fleming I, Munzel T. Mechanisms of increased vascular superoxide production in an experimental model of idiopathic dilated cardiomyopathy. Arterioscler Thromb Vasc Biol. 2005;25:2554-2559.
2. Elkayam U, Mehra A, Shotan A, Ostrzega E. Nitrate resistance and tolerance: potential limitations in the treatment of congestive heart failure. Am J Cardiol. 1992;70:98B-104B.
3. Munzel T, Daiber A, Mulsch A. Explaining the phenomenon of nitrate tolerance. Circ Res. 2005;97:618-628.
4. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG. Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest. 1995;95:187-194.
5. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol. 1996;50:1-5.
6. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5:755-768.
7. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch J-P, Burnett JC Jr. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension. 2007;49:1128-1133.
8. Ziesche S, Cobb FR, Cohn JN, Johnson G, Tristani F. Hydralazine and isosorbide dinitrate combination improves exercise tolerance in heart failure. Results from V-HeFT I and V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87:VI56-VI64.
9. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R Jr, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049-2057.
10. Daiber A, Oelze M, Coldewey M, Kaiser K, Huth C, Schildknecht S, Bachschmid M, Nazirisadeh Y, Ullrich V, Mulsch A, Munzel T, Tsilimingas N. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun. 2005;338:1865-1874.
11. Munzel T, Kurz S, Rajagopalan S, Thoenes M, Berrington WR, Thompson JA, Freeman BA, Harrison DG. Hydralazine prevents nitroglycerin tolerance by inhibiting activation of a membrane-bound NADH oxidase. A new action for an old drug. J Clin Invest. 1996;98:1465-1470.